Loading company…
Massachusetts-based biotech developing stromal cell-derived therapeutic proteins for cardiovascular disease and diabetic ulcers.
Founded in 2007 and based in Cambridge, Massachusetts, US, Provasculon, Inc. develops novel forms of stromal cell-derived therapeutic proteins to treat patients with cardiovascular diseases and diabetic ulcers. It is listed at the Series A stage.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in